Literature DB >> 16942672

Seizure aggravation by antiepileptic drugs.

Ernest R Somerville1.   

Abstract

Seizure aggravation by antiepileptic drugs (AEDs) is an overestimated phenomenon. While it undoubtedly occurs, the quality of evidence in most published reports is poor. Although seizure aggravation can be examined in clinical trials in the same way as seizure improvement, this is rarely done. Before concluding that an increase in seizures after the introduction of a new drug represents pharmacodynamic aggravation, alternative explanations should be explored. These include spontaneous fluctuation of seizure frequency, the presence of known seizure aggravators (such as sleep deprivation, alcohol, and psychotropic medications), progression of epilepsy, the development of drug resistance, and replacement of a partially effective drug with a less effective drug. The risk of incorrectly blaming a drug for a deterioration in seizures can be minimized by establishing baseline seizure frequency over a period long enough to encompass the extremes of seizure fluctuation and by educating the patient that a temporal relationship may not be a causal relationship. When feasible, the patient should continue the drug long enough to establish if the deterioration is transient. If the drug is stopped, rechallenge should be considered. The risk of seizure aggravation can be minimized by accurate diagnosis of the epilepsy syndrome and appropriate choice of AED.

Entities:  

Year:  2006        PMID: 16942672     DOI: 10.1007/s11940-006-0019-5

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.972


  38 in total

Review 1.  Seizure aggravation in idiopathic generalized epilepsies.

Authors:  J Chaves; J W Sander
Journal:  Epilepsia       Date:  2005       Impact factor: 5.864

Review 2.  Practical management issues for idiopathic generalized epilepsies.

Authors:  Selim R Benbadis
Journal:  Epilepsia       Date:  2005       Impact factor: 5.864

Review 3.  Seizure-inducing effects of antiepileptic drugs: a review.

Authors:  J Bauer
Journal:  Acta Neurol Scand       Date:  1996-12       Impact factor: 3.209

4.  Benzodiazepine sensitivity testing in the management of intractable seizure disorders in childhood.

Authors:  J H Livingston; A Anderson; J K Brown; A McInnes
Journal:  Electroencephalogr Clin Neurophysiol       Date:  1987-09

Review 5.  Antiepileptic drugs as a cause of worsening seizures.

Authors:  E Perucca; L Gram; G Avanzini; O Dulac
Journal:  Epilepsia       Date:  1998-01       Impact factor: 5.864

6.  Tonic status epilepticus precipitated by intravenous benzodiazepine in five patients with Lennox-Gastaut syndrome.

Authors:  C A Tassinari; C Dravet; J Roger; J P Cano; H Gastaut
Journal:  Epilepsia       Date:  1972-07       Impact factor: 5.864

7.  Treatment of epilepsy in adults: expert opinion, 2005.

Authors:  Steven Karceski; Martha J Morrell; Daniel Carpenter
Journal:  Epilepsy Behav       Date:  2005-09       Impact factor: 2.937

8.  Worsening of seizures by oxcarbazepine in juvenile idiopathic generalized epilepsies.

Authors:  Philippe Gelisse; Pierre Genton; Callixte Kuate; Aurélie Pesenti; Michel Baldy-Moulinier; Arielle Crespel
Journal:  Epilepsia       Date:  2004-10       Impact factor: 5.864

9.  Gabapentin in partial epilepsy. UK Gabapentin Study Group.

Authors: 
Journal:  Lancet       Date:  1990-05-12       Impact factor: 79.321

10.  Tonic status epilepticus presenting as confusional state.

Authors:  E R Somerville; J Bruni
Journal:  Ann Neurol       Date:  1983-05       Impact factor: 10.422

View more
  2 in total

1.  Case files of the University of California San Francisco Medical Toxicology Fellowship: lamotrigine toxicity.

Authors:  Michelle Fleurat; Craig Smollin
Journal:  J Med Toxicol       Date:  2012-03

2.  Antiepileptic drug monotherapy: the initial approach in epilepsy management.

Authors:  Erik K St Louis; William E Rosenfeld; Thomas Bramley
Journal:  Curr Neuropharmacol       Date:  2009-06       Impact factor: 7.363

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.